A Study to Assess the Bioavailability and Adhesion of Estradiol/Levonorgestrel TDS in Healthy Post-Menopausal Female Participants
brief summary
The purpose of this study is to compare the bioequivalence and adhesion performance of a test estradiol/levonorgestrel transdermal delivery system (TDS) with the reference product, Climara Pro® (estradiol/levonorgestrel transdermal system), following a single 7-day application in healthy postmenopausal female participants. The study will also evaluate the safety and tolerability of the test and reference patches.
detailed description
This is an open-label, balanced, randomized, two-treatment, two-period, two-sequence crossover study designed to compare the bioequivalence and adhesion performance of a test estradiol/levonorgestrel transdermal delivery system (TDS) with the reference product, Climara Pro® (estradiol/levonorgestrel transdermal system), in healthy postmenopausal female participants.
Approximately 68 healthy, non-tobacco- and non-nicotine-using postmenopausal female participants will be randomized to one of two treatment sequences. Participants will receive a single application of the test product in one study period and a single application of the reference product in the other study period, according to the assigned randomization sequence. Each patch will be applied for 168 hours (7 days), and the two treatment periods will be separated by a washout interval of at least 21 days between application days.
Serial blood samples will be collected following patch application to characterize plasma concentrations of estradiol and levonorgestrel and to evaluate bioequivalence between the test and reference products. Patch adhesion will be assessed at prespecified time points throughout the 7-day wear period using a standardized adhesion scoring system. Skin irritation assessments will be performed before application and following patch removal according to protocol-defined procedures.
Safety and tolerability will be evaluated throughout the study through monitoring of adverse events, concomitant medications, clinical laboratory assessments, vital signs, physical examinations, and other protocol-specified safety evaluations.
The study is intended to evaluate whether the pharmacokinetic performance and adhesion characteristics of the test estradiol/levonorgestrel transdermal delivery system are comparable to those of the reference product following a single application in healthy postmenopausal female participants.
official title
A Study to Compare the Bioequivalence and Adhesion Between a Test Estradiol/Levonorgestrel Transdermal Delivery System (0.045 mg Per Day/0.015 mg Per Day) (Corium TDS) and Reference Climara Pro® at the Same Strength (0.045 mg Per Day / 0.015 mg Per Day) for Seven Days in Post-menopausal Female Participants